Discontinuing GLP-1 drugs linked to higher cardiovascular risk in veterans study
A study of over 333,000 U.S. veterans with type 2 diabetes found that stopping GLP-1 medications for six months or more increased the risk of major cardiovascular events. After two years off treatment, the risk of heart attack, stroke, and death was up to 22% higher than for those who continued. The findings highlight the importance of uninterrupted treatment for maintaining heart protection.
The study tracked 333,687 veterans with type 2 diabetes over three years, comparing those prescribed GLP-1 drugs against users of sulfonylureas. Roughly a quarter of GLP-1 users stopped treatment entirely, while another quarter experienced gaps of at least six months. Researchers reassessed medication status every six months to track how lapses affected cardiovascular outcomes.
The heart-protective effect appears tied to continuous use. Restarting medication restored only partial benefit, suggesting lasting consequences from interruption. The researchers describe a "metabolic whiplash" effect, where stopping triggers resurgence in inflammation, blood pressure, and cholesterol—changes that are invisible to patients, unlike the visible weight regain they often notice.
This research could reshape how physicians and patients approach GLP-1 therapy, especially since about half of users discontinue within months due to cost, side effects, or supply shortages. If the findings hold, patients who pause treatment may face elevated heart risks they cannot see, potentially influencing prescribing practices, insurance coverage decisions, and patient education. The study may also prompt broader conversations about long-term medication adherence in chronic disease management.